Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

Bayer wins MHRA approval for Kerendia in heart failure

 April 13, 2026

PharmaTimes

New authorisation offers additional option for patients with lvef 40%

RegulatoryCardiovascularRead full story

Post navigation

Oricell closes a ‘pre-IPO’ megaround to aim CAR-T at solid tumors →
← FDA hands another rejection to Replimune’s melanoma therapy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com